5/6/2024 | 2:15 PM – 3:30 PM | Exhibit Hall F1
Late Breaking - Therapeutic Approaches to Autoimmunity (PM)
Maresin-1 attenuates neuroinflammation in EAE via metabolic reprogramming of disease-associated cell types
(P898)Presentation Time: 02:15 PM–03:30 PM
Posterboard Number: 898
Abstract ID: 6187
Presenting Author:
Insha Zahoor, Henry Ford Hlth.
Co-Authors:
Mohammad Nematullah, Henry Ford Hlth.; Mohammad Ejaz Ahmed, Henry Ford Hlth.; Mena Fatma, Henry Ford Hlth.; Sajad Mir, Henry Ford Hlth.; Ramandeep Rattan, Henry Ford Hlth.; Shailendra Giri, Henry Ford Hlth.;
View Abstract Details
Development of highly selective, potent, orally available PIM1 inhibitor BLX-0631 shows a therapeutics potential in Systemic Lupus Erythematosus (SLE) models
(P900)Presentation Time: 02:15 PM–03:30 PM
Posterboard Number: 900
Abstract ID: 6301
Presenting Author:
Hariprasad Vankayalapati, Biolexis Therapeut.
Co-Authors:
Chenyu Lin; Zhaoliang Li; Kyle Medley; David J Bearss, Biolexis Therapeut.;
View Abstract Details
Efficacy evaluation of B cell targeting drugs and the involved mechanism of action study in humanized BAFF transgenic SLE mice model
(P902)Presentation Time: 02:15 PM–03:30 PM
Posterboard Number: 902
Abstract ID: 6470
Presenting Author:
Juan Liang
Co-Authors:
Shuxin Xu; Qiuping Xu; Yuxi Zhang;
View Abstract Details
Development of conditionally active IL-10 INDUKINETM molecules for the treatment of inflammatory bowel disease
(P906)Presentation Time: 02:15 PM–03:30 PM
Posterboard Number: 906
Abstract ID: 6850
Presenting Author:
Jenna M Sullivan, Werewolf Therapeut.
Co-Authors:
Pamela A Aderhold, Werewolf Therapeut.; Heather R Brodkin, Werewolf Therapeut.; Celesztina Nagy-Domonkos, Werewolf Therapeut.; Kyriakos Economides, Werewolf Therapeut.; Daniel J Hicklin, Werewolf Therapeut.; Yuka Lewis, Werewolf Therapeut.; Leigh Magness, Werewolf Therapeut.; Cynthia Siedel-Dugan, Werewolf Therapeut.; Zoe Steuert, Werewolf Therapeut.; Jessica Stieglitz, Werewolf Therapeut.; William M Winston, Werewolf Therapeut.; Andres Salmerson, Werewolf Therapeut.;
View Abstract Details
Pharmacological activation of LANCL receptors has three-fold benefit in metabolic dysfunction-associated steatohepatitis
(P908)Presentation Time: 02:15 PM–03:30 PM
Posterboard Number: 908
Abstract ID: 7426
Presenting Author:
Andrew J Leber, NIMML Inst.
Co-Authors:
Raquel Hontecillas, NIMML Inst.; Nuria Tubau-Juni, NIMML Inst.; Sarah N Fitch, NIMML Inst.; Josep Bassaganya-Riera, NIMML Inst.;
View Abstract Details
Pharmacological activation of LANCL2 ameliorates disease severity and decreases inflammation in a preclinical model of rheumatoid arthritis
(P910)Presentation Time: 02:15 PM–03:30 PM
Posterboard Number: 910
Abstract ID: 7473
Presenting Author:
Nuria Tubau-Juni, NIMML Inst.
Co-Authors:
Raquel Hontecillas, NIMML Inst.; Andrew Leber, NIMML Inst.; Josep Bassaganya-Riera, NIMML Inst.;
View Abstract Details